Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections

doi:10.1016/j.micinf.2014.11.008

Review

. 2015 Feb;17(2):142-8.

doi: 10.1016/j.micinf.2014.11.008. Epub 2014 Nov 29.

Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections

Tianlei Ying¹, Haoyang Li², Lu Lu², Dimiter S Dimitrov³, Shibo Jiang⁴

Affiliations

¹ Key Laboratory of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Rd., Shanghai 200032, China. Electronic address: tlying@fudan.edu.cn.
² Key Laboratory of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Rd., Shanghai 200032, China.
³ Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.
⁴ Key Laboratory of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Rd., Shanghai 200032, China; Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.

PMID: 25456101
PMCID: PMC4308519
DOI: 10.1016/j.micinf.2014.11.008

Review

Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections

Tianlei Ying et al. Microbes Infect. 2015 Feb.

. 2015 Feb;17(2):142-8.

doi: 10.1016/j.micinf.2014.11.008. Epub 2014 Nov 29.

Authors

Tianlei Ying¹, Haoyang Li², Lu Lu², Dimiter S Dimitrov³, Shibo Jiang⁴

Affiliations

¹ Key Laboratory of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Rd., Shanghai 200032, China. Electronic address: tlying@fudan.edu.cn.
² Key Laboratory of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Rd., Shanghai 200032, China.
³ Protein Interactions Section, Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA.
⁴ Key Laboratory of Medical Molecular Virology of MOE/MOH, Shanghai Medical College, Fudan University, 130 Dong An Rd., Shanghai 200032, China; Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA.

PMID: 25456101
PMCID: PMC4308519
DOI: 10.1016/j.micinf.2014.11.008

Abstract

The recent Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak poses a serious threat to public health. Here, we summarize recent advances in identifying human neutralizing monoclonal antibodies (mAbs) against MERS-CoV, describe their mechanisms of action, and analyze their potential for treatment of MERS-CoV infections.

Keywords: Coronavirus; MERS-CoV; Receptor binding domain (RBD); mAbs.

PubMed Disclaimer

Figures

**Fig. 1**
Schematic illustration of the inhibition of MERS-CoV cell entry by neutralizing mAbs, mAb cocktails, bispecific antibodies, antibody-durg conjugates, and novel monomeric antibody constructs.

See this image and copyright information in PMC

Cited by

Coronavirus membrane fusion mechanism offers a potential target for antiviral development.
Tang T, Bidon M, Jaimes JA, Whittaker GR, Daniel S. Tang T, et al. Antiviral Res. 2020 Jun;178:104792. doi: 10.1016/j.antiviral.2020.104792. Epub 2020 Apr 6. Antiviral Res. 2020. PMID: 32272173 Free PMC article. Review.
Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS).
Lu L, Xia S, Ying T, Jiang S. Lu L, et al. Emerg Microbes Infect. 2015 Jun 17;4(6):e37. doi: 10.1038/emi.2015.37. Emerg Microbes Infect. 2015. PMID: 26954884 Free PMC article. No abstract available.
3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012.
Johnson RF, Bagci U, Keith L, Tang X, Mollura DJ, Zeitlin L, Qin J, Huzella L, Bartos CJ, Bohorova N, Bohorov O, Goodman C, Kim DH, Paulty MH, Velasco J, Whaley KJ, Johnson JC, Pettitt J, Ork BL, Solomon J, Oberlander N, Zhu Q, Sun J, Holbrook MR, Olinger GG, Baric RS, Hensley LE, Jahrling PB, Marasco WA. Johnson RF, et al. Virology. 2016 Mar;490:49-58. doi: 10.1016/j.virol.2016.01.004. Epub 2016 Jan 30. Virology. 2016. PMID: 26828465 Free PMC article.
Identification of Human Single-Domain Antibodies against SARS-CoV-2.
Wu Y, Li C, Xia S, Tian X, Kong Y, Wang Z, Gu C, Zhang R, Tu C, Xie Y, Yang Z, Lu L, Jiang S, Ying T. Wu Y, et al. Cell Host Microbe. 2020 Jun 10;27(6):891-898.e5. doi: 10.1016/j.chom.2020.04.023. Epub 2020 May 14. Cell Host Microbe. 2020. PMID: 32413276 Free PMC article.
Treatment strategies for Middle East respiratory syndrome coronavirus.
Modjarrad K. Modjarrad K. J Virus Erad. 2016;2(1):1-4. doi: 10.1016/S2055-6640(20)30696-8. J Virus Erad. 2016. PMID: 26866060 Free PMC article.

See all "Cited by" articles

References

1. Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820. - PubMed
1. Lu L., Liu Q., Du L., Jiang S. Middle east respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microb Infect. 2013;15:625–629. - PMC - PubMed
1. Hotez P.J., Bottazzi M.E., Tseng C.T., Zhan B., Lustigman S., Du L. Calling for rapid development of a safe and effective MERS vaccine. Microb Infect. 2014;16:529–531. - PMC - PubMed
1. Dimitrov D.S. Therapeutic proteins. Methods Mol Biol. 2012;899:1–26. - PMC - PubMed
1. Carter P.J. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343–357. - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

Z99 CA999999/Intramural NIH HHS/United States

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations

[1] Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820. - PubMed

[2] Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820. - PubMed

[3] Lu L., Liu Q., Du L., Jiang S. Middle east respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microb Infect. 2013;15:625–629. - PMC - PubMed

[4] Lu L., Liu Q., Du L., Jiang S. Middle east respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microb Infect. 2013;15:625–629. - PMC - PubMed

[5] Hotez P.J., Bottazzi M.E., Tseng C.T., Zhan B., Lustigman S., Du L. Calling for rapid development of a safe and effective MERS vaccine. Microb Infect. 2014;16:529–531. - PMC - PubMed

[6] Hotez P.J., Bottazzi M.E., Tseng C.T., Zhan B., Lustigman S., Du L. Calling for rapid development of a safe and effective MERS vaccine. Microb Infect. 2014;16:529–531. - PMC - PubMed

[7] Dimitrov D.S. Therapeutic proteins. Methods Mol Biol. 2012;899:1–26. - PMC - PubMed

[8] Dimitrov D.S. Therapeutic proteins. Methods Mol Biol. 2012;899:1–26. - PMC - PubMed

[9] Carter P.J. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343–357. - PubMed

[10] Carter P.J. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343–357. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections

Affiliations

Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections

Authors

Affiliations

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources